Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
about
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-AnalysesThe Role of MicroRNAs in Diabetic Complications-Special Emphasis on Wound HealingAngiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium riskProtection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease.Management of Hypertension Using Olmesartan Alone or in CombinationEffects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies.The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: a representative cohort study in TaiwanThe Effect of Renin-Angiotensin-Aldosterone System Blockade Medications on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Meta-AnalysisEffects of ACEIs Versus ARBs on Proteinuria or Albuminuria in Primary Hypertension: A Meta-Analysis of Randomized TrialsChange in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitorsThe Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease.The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation.Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme InhibitorsA comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in TaiwanComparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy.Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial.Blood pressure control in type 2 diabetic patients.Correlation of angiotensin I-converting enzyme gene insertion/deletion polymorphism with rheumatic heart disease: a meta-analysis.The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis.Treating hypertension in type 2 diabetes.Novel effective drugs for diabetic kidney disease? or not?Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure.Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence?Glucose Homeostasis and Cardiovascular Alterations in Diabetes.The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease.Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to?Phase 4 Studies in Heart Failure - What is Done and What is Needed?Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the U.K. Clinical Practice Research Datalink.Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial InfarctA prospective study of frequency and characteristics of cough during ACE inhibitor treatment.Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease.Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients.Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trialsPerindopril for improving cardiovascular events.Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes.The Effect of Monthly Medication on Mortality After a Coronary Event.
P2860
Q26767278-AC0FB8B2-3ABE-4F00-B887-A5B709D80161Q26827627-3E15CC47-957B-4747-B429-E92D3913BEDEQ26851803-CB1727E4-02D9-4DBA-B442-87C3B47706AAQ27687851-60FF2B0E-5C2C-4DCD-A17D-611ECF122D9BQ28543493-CF45A584-9303-4B6D-BF21-F86C222CE10AQ30249156-4293E786-2344-44FE-A4FF-9A57379FC6E8Q33734043-23A3D8E4-D6B1-4731-A3EE-1042FA5394CBQ34459963-207273C5-01BD-4A41-B00D-FC483A9945EEQ35391563-613CAB1A-2787-4F6E-9AC1-6FCF78A3FF00Q35666177-C7E86350-C978-4F6F-AECE-44C1E0E448EAQ36195895-53C88D25-E1C6-4EEF-A948-12070F07BE1AQ36203442-2E86D748-C5E7-4F87-AFDF-B9319B3FBB21Q36259972-6FF6FFD4-B325-49F3-A648-6B605E4AC049Q36417449-16AE1C4F-DBA2-44FD-B5BC-F5F1EAA26BF2Q36421103-DB5A24CF-7329-4D5D-B009-D0CDD7E25721Q36759789-ABFED21E-0289-4C57-95F7-5073EB7C1C3BQ36905430-1E0FBD1A-6ABD-4AA3-B1A5-5E449D96056DQ36930155-827AFE36-35EB-4B2E-82A9-35ECF290062FQ37566950-86C47764-A3D1-47DF-B3A7-8B6A8FC8BD2CQ37626803-A068BA2B-15BC-4C7B-B318-E91BBE86ED79Q37737326-B504B93F-C51D-4DBF-AD7C-2C7D63E54069Q38236013-10984DF7-1D82-4C85-A5F1-BA78D030EDF0Q38265818-DE9DB967-880F-4AFD-B1D6-FB555344734CQ38373783-E9320F05-B36C-4D79-9983-89F4FDDEECB7Q38409909-C1AFBA7F-A96B-4140-96EF-5BDCF0C24EC8Q38596700-EB33FD96-1D45-49C9-BB1A-39F9F7816FD5Q38767234-BDAF4F09-AE0B-45E4-8B45-F5D78E4F04EFQ38770466-5AEBC476-B287-4B60-9FD6-5541831DFD05Q38859866-E813ACFF-33DA-4552-834C-463AA9D9D49DQ39532143-1E82119C-40D5-4AE3-9590-6F6A46DDA7C4Q39816079-B1595DF3-18C5-4455-BF1C-95B82A61AF4AQ40022621-EA40EDFF-6D9B-4D94-B94C-96094F042A81Q40759735-5A768C90-0420-45D4-96A6-D98C46D68BE9Q40920242-0BE86B34-17BA-40CF-AB26-8D677C5BEB29Q41564747-362CDEDD-162F-49DF-8D9E-5440B7C072ACQ41712920-73ACDD78-A510-4E30-A2CD-A70C4D1D2E2BQ42276363-A34AEC9C-77AF-472E-ABEB-89A625B4C180Q42864618-E6C327CE-AF48-4942-A482-CA1ADA979F9DQ47834402-FB35191E-8DB7-4394-AFEF-A7830305BAFAQ48244402-69D94494-7734-419C-BCD1-D2C9632E61F6
P2860
Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effect of angiotensin-converti ...... tes mellitus: a meta-analysis.
@ast
Effect of angiotensin-converti ...... tes mellitus: a meta-analysis.
@en
Effect of angiotensin-converti ...... tes mellitus: a meta-analysis.
@nl
type
label
Effect of angiotensin-converti ...... tes mellitus: a meta-analysis.
@ast
Effect of angiotensin-converti ...... tes mellitus: a meta-analysis.
@en
Effect of angiotensin-converti ...... tes mellitus: a meta-analysis.
@nl
prefLabel
Effect of angiotensin-converti ...... tes mellitus: a meta-analysis.
@ast
Effect of angiotensin-converti ...... tes mellitus: a meta-analysis.
@en
Effect of angiotensin-converti ...... tes mellitus: a meta-analysis.
@nl
P2093
P921
P1476
Effect of angiotensin-converti ...... tes mellitus: a meta-analysis.
@en
P2093
Jianghua Chen
Xiaohui Zhang
P304
P356
10.1001/JAMAINTERNMED.2014.348
P577
2014-05-01T00:00:00Z